← Library
LL-37 (Cathelicidin)
Research Use
Also known as hCAP18 peptide
Interaction Warning1 flagged
Do not combine LL-37 (Cathelicidin) with the following:
- Autoimmune flares
Function
Primary
Antimicrobial · Wound healing
Secondary
Immunomodulation
Mechanism
Human cathelicidin antimicrobial peptide — disrupts bacterial membranes; modulates TLR signaling; promotes keratinocyte migration; anti-biofilm.
Evidence
Pre-clinical / Observational
Research
Pre-clinical and in vitro primarily
Dosing
Range
Not standardized for human use
Frequency
Variable
Route
Topical · Intralesional (research)
Administration & Technique
Topical
Cosmetic / dermal repair peptides applied directly to skin.
DeviceSerum, cream, or gel formulation.
TechniqueApply to clean dry skin AM/PM. Wait 60–90 sec before layering moisturizer or sunscreen. Separate copper peptides from vitamin C / AHA by ≥12 hrs (copper is destabilized).
Injection & Application Sites
Front
Back
Topical
- Face / neck (topical) — Clean dry skin, AM and PM, before moisturizer.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Not standardized.
Timing & Interactions
When to take
Daily SubQ, morning. Short cycles (2–4 weeks) to minimize immune fatigue.
Do not combine with
- ·Autoimmune flares — may aggravate
Complements
- ·Thymosin Alpha-1
Storage & Reconstitution
Powder (Pre-Reconstitution)
Lyophilized powder: refrigerate 2–8°C for up to 24 months, or freeze at –20°C for extended storage. Keep sealed, desiccated, and protected from light.
After Reconstitution
After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Discard if cloudy, discolored, or precipitated.
Notes
Do not freeze after reconstitution — freeze/thaw cycles degrade most peptides.
Reconstitution Calculator
Concentration
2.50 mg/mL
Volume per dose
0.100 mL
Insulin syringe
10.0 units (U-100)
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Your Notes
Sign in to save personal notes on LL-37 (Cathelicidin) and sync them to Vial Lab.
Benefits
- ·Broad antimicrobial activity
- ·Wound healing in models
- ·Biofilm disruption
Risks
- ·Pro-inflammatory at high doses
- ·Potential oncogenicity in some cancer models
Contraindications
- ·Active malignancy (theoretical)
- ·Pregnancy
Regulatory
Not FDA-approved; research use
Veterinary Use (Pets)
No established veterinary protocol for LL-37 (Cathelicidin). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
- Vandamme D et al. A comprehensive summary of LL-37. Cell Immunol. 2012;280:22.source